x

Posted 01 September, 2022

SWK Holdings Corp appointed Jody Staggs as new CEO

Nasdaq:SWKH appointed new Chief Executive Officer Jody Staggs in a 8-K filed on 01 September, 2022.


  The Company's Board of Directors has appointed Jody Staggs to be the Company's President, effective as of September 1, 2022, and the Interim Chief Executive Officer of the Company, effective as of the Separation Date.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of SWK Holdings Corp
Technology • Software
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.
Market Cap
$204M
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


On September 1, 2022, SWK Holdings Corporation (the "Company") announced that the Company and Winston L. Black III, Chief Executive Officer of the Company and a member of its Board of Directors have mutually agreed that Mr. Black would depart from his current positions with the Company, effective September 30, 2022 (the "Separation Date"). The Company's Board of Directors has appointed Jody Staggs to be the Company's President, effective as of September 1, 2022, and the Interim Chief Executive Officer of the Company, effective as of the Separation Date. 


The Company and Mr. Black entered into a Separation and Release Agreement, dated August 31, 2022 (the "Separation Agreement"), pursuant to which Mr. Black has agreed to serve as a non-employee consultant to the Company for the six-month period following the Separation Date, providing certain advisory services to the Company, including assisting in transitioning duties and responsibilities and providing advice on matters related to the business. In consideration of the provision of these consulting services and subject to Mr. Black's execution of a general release of claims and compliance with the terms of the Separation Agreement, including restrictive covenants set out therein, Mr. Black will be entitled to receive the following: (i) six months of continued base salary ($150,250 in total) beginning from the Separation Date; (ii) a monthly payment for a period of six months from the Separation Date equal to the cost of COBRA continuation coverage under the Company's medical plans less the amount of Mr. Black's portion of the premium as if Mr. Black were an active employee; (iii) a lump sum payment of $1,100,000, payable 30 days after the Separation Date; (iv) payout of accrued vacation; and (v) reimbursement of legal fees up to $10,000. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, a copy of which will be filed with the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2022.


Mr. Staggs, 41, was a co-founder of PBS Capital, an investment management firm focused on pharmaceutical royalties and healthcare equities, which was a predecessor to the Company's specialty finance business. He joined the Company in August 2015 and was promoted to Managing Director in January 2020. Prior to joining the Company, Mr. Staggs was a Vice President of Investments at Annandale Capital, an employee at Dallas-based hedge fund Alistair Capital and a Senior Portfolio Analyst at Highland Capital. He began his career as an equity research associate at Raymond James, and he was a Walton Scholar and on the Dean's List at the University of Arkansas where he graduated with a B.A. in Finance. He has earned the right to use the Chartered Financial Analyst designation. The Company expects to enter into an employment agreement with Mr. Staggs in connection with his appointment as the Company's President and Interim Chief Executive Officer. The material terms of the employment agreement will be disclosed upon its finalization. There are no family relationships between Mr. Staggs and any director or executive officer of the Company, and the Company has not entered into any transactions with Mr. Staggs that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Mr. Staggs and any other persons pursuant to which he was appointed.